HBx mutants differentially affect the activation of hypoxia-inducible factor-1α in hepatocellular carcinoma

British Journal of Cancer

Volumn 110, Issue 4, 2014, Pages 1066-1073

  Liu, L P ^a,b   Hu, B G ^a   Ye, C ^a   Ho, R L K ^a   Chen, G G ^a   Lai, P B S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b SHENZHEN PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HEPATITIS B VIRUS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS; POINT MUTATION; SEQUENCE ANALYSIS, DNA; TRANS-ACTIVATORS; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; UP-REGULATION;

EID: 84894321550     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.787     Document Type: Article

References (24)

1. Asim M, Malik A, Sarma MP, Polipalli SK, Begum N, Ahmad I, Khan LA, Husain SA, Akhtar N, Husain S, Thayumanavan L, Singla R, Kar P (2010) Hepatitis B virus BCP, Precore/core, X gene mutations/genotypes and the risk of hepatocellular carcinoma in India. J Med Virol 82: 1115-1125.
2. Chen CJ, Yang HI (2011) Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 26: 628-638.
3. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295: 65-73.
4. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ (2001) C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54.
5. Harris AL (2002) Hypoxia-A key regulatory factor in tumour growth. Nat Rev 2: 38-47.
6. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin Jr. WG (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science 292: 464-468.
7. Iyer S, Groopman JD (2011) Interaction of mutant hepatitis B X protein with p53 tumor suppressor protein affects both transcription and cell survival. Mol Carcinog 50: 972-980.
8. Kumar V, Jayasuryan N, Kumar R (1996) A truncated mutant (residues 58-140) of the hepatitis B virus X protein retains transactivation function. Proc Natl Acad Sci USA 93: 5647-5652.
9. Liu LP, Ho RL, Chen GG, Lai P (2012) Sorafenib inhibits hypoxia-inducible factor-1alpha synthesis: Implications for anti-Angiogenic activity in hepatocellular carcinoma. Clin Cancer Res 18: 5662-5671.
10. Liu LP, Liang HF, Chen XP, Zhang WG, Yang SL, Xu T, Ren L (2010) The role of NF-kappaB in Hepatitis b virus X protein-mediated upregulation of VEGF and MMPs. Cancer Invest 28: 443-451.
11. Lizzano RA, Yang B, Clippinger AJ, Bouchard MJ (2011) The C-Terminal region of the hepatitis B virus X protein is essential for its stability and function. Virus Res 155: 231-239.
12. Lucifora J, Arzberger S, Durantel D, Belloni L, Strubin M, Levrero M, Zoulim F, Hantz O, Protzer U (2011) Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol 55: 996-1003.
13. Ma NF, Lau SH, Hu L, Xie D, Wu J, Yang J, Wang Y, Wu MC, Fung J, Bai X, Tzang CH, Fu L, Yang M, Su YA, Guan XY (2008) COOH-Terminal truncated HBV X protein plays key role in hepatocarcinogenesis. Clin Cancer Res 14: 5061-5068.
14. Neuveut C, Wei Y, Buendia MA (2010) Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol 52: 594-604.
15. Ng SA, Lee C (2011) Hepatitis B virus X gene and hepatocarcinogenesis. J Gastroenterol 46: 974-990.
16. Pouyssegur J, Dayan F, Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441: 437-443.
17. Rui E, Moura PR, Goncalves Kde A, Kobarg J (2005) Expression and spectroscopic analysis of a mutant hepatitis B virus onco-protein HBx without cysteine residues. J Virol Methods 126: 65-74.
18. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev 3: 721-732.
19. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
20. Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, Wang LY, Lu SN, You SL, Chen DS, Liaw YF, Chen CJ (2008) Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 100: 1134-1143.
21. Yip WK, Cheng AS, Zhu R, Lung RW, Tsang DP, Lau SS, Chen Y, Sung JG, Lai PB, Ng EK, Yu J, Wong N, To KF, Wong VW, Sung JJ, Chan HL (2011) Carboxyl-Terminal truncated HBx regulates a distinct microRNA transcription program in hepatocellular carcinoma development. PLoS One 6: E22888.
22. Yoo YG, Lee MO (2004) Hepatitis B virus X protein induces expression of Fas ligand gene through enhancing transcriptional activity of early growth response factor. J Biol Chem 279: 36242-36249.
23. Yoo YG, Na TY, Seo HW, Seong JK, Park CK, Shin YK, Lee MO (2008) Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells. Oncogene 27: 3405-3413.
24. Yoo YG, Oh SH, Park ES, Cho H, Lee N, Park H, Kim DK, Yu DY, Seong JK, Lee MO (2003) Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-1alpha through activation of mitogen-Activated protein kinase pathway. J Biol Chem 278: 39076-39084.